Actively Recruiting
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Led by BeiGene · Updated on 2026-04-22
200
Participants Needed
29
Research Sites
467 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
CONDITIONS
Official Title
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of malignancy
- Locally advanced unresectable or metastatic solid tumors with MSI-H or dMMR
- Prior cancer therapy regimen(s) for advanced disease received
- At least 1 measurable lesion per RECIST Version 1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or other T-cell co-stimulation/checkpoint pathway targeting drugs
- Active leptomeningeal disease or uncontrolled brain metastasis
- Clinically significant pleural effusion, pericardial effusion, or ascites
- Active autoimmune diseases or history of autoimmune diseases that may relapse
- Any active malignancy
- Systemic corticosteroids (>10 mg prednisone daily or equivalent) or immunosuppressive medication use within 14 days before study drug
- History of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis, acute lung diseases, or uncontrolled systemic diseases
- Uncontrolled diabetes or uncontrolled electrolyte disorders despite standard management
- Severe chronic or active infections
- Known HIV infection
- Child-Pugh B or greater cirrhosis
- Major surgery within 28 days before first dose
- Prior allogeneic stem cell or organ transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 29 locations
1
Anhui Provincial Hospital
Hefei, Anhui, China, 230000
Completed
2
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Completed
3
The Affiliated Hospital of Military Medical Sciences
Beijing, Beijing Municipality, China, 100071
Completed
4
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
5
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
6
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
7
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China, 510080
Completed
8
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510515
Completed
9
The Sixth Affiliated Hospital, Sun Yat Sen University
Guangzhou, Guangdong, China, 510655
Completed
10
Huizhou First Hospital
Huizhou, Guangdong, China, 516000
Actively Recruiting
11
Meizhou People Hospital
Meizhou, Guangdong, China, 514031
Actively Recruiting
12
The Peoples Hospital of Hechi
Hechi, Guangxi, China, 547099
Actively Recruiting
13
Affiliated Hospital of Hebei University
Baoding, Hebei, China, 071000
Completed
14
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150000
Actively Recruiting
15
Henan Cancer Hospital
Zhengzhou, Henan, China, 450000
Completed
16
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Completed
17
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Completed
18
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Completed
19
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China, 210008
Completed
20
Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029
Completed
21
Jilin Cancer Hospital
Changchun, Jilin, China, 130021
Completed
22
The General Hospital of Shenyang Military
Shenyang, Liaoning, China, 110016
Completed
23
Yidu Central Hospital of Weifang
Weifang, Shandong, China, 262550
Actively Recruiting
24
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200000
Completed
25
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200032
Completed
26
The First Peoples Hospital of Yibin
Yibin, Sichuan, China, 644000
Actively Recruiting
27
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Completed
28
Zhejiang University College of Medicine Second Affiliated Hospital
Hangzhou, Zhejiang, China, 310009
Completed
29
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Completed
Research Team
B
BeiGene
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here